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Abstract
Background: Although described by Hippocrates in 400 B.C., pemphigus disease still needs a safe
therapeutical approach, given that the currently used therapies (i.e. corticosteroids and
immunosuppressive drugs) often provoke collateral effects. Here we present preliminary data on
the possible use of a proteomics derived desmoglein peptide which appears promising in halting
disease progression without adverse effects.
Methods: The low-similarity Dsg349–60REWVKFAKPCRE peptide was topically applied for 1 wk
onto a lesion in a patient with a late-stage Pemphigus vulgaris (PV) complicated by diabetes and
cataract disease. The peptide was applied as an adjuvant in combination with the standard
corticosteroid-based immunosuppressive treatment.
Results: After 1 wk, the treated PV eroded lesion appeared dimensionally reduced and with an
increased rate of re-epithelization when compared to adjacent non-treated lesions. Short-term
benefits were: decrease of anti-Dsg antibody titer and reduction of the corticosteroid dosage.
Long-term benefits: after two years following the unique 1-wk topical treatment, the decrease of
anti-Dsg antibody titer persists. The patient is still at the low cortisone dosage. Adverse effects: no
adverse effect could be monitored.
Conclusion: With the limits inherent to any preliminary study, this case report indicates that
topical treatment with Dsg349–60REWVKFAKPCRE peptide may represent a feasible first step in
the search for a simple, effective and safe treatment of PV.
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Background
Pemphigus vulgaris (PV) is a rare, but severe immune-medi-
ated blistering skin disease mediated by autoantibodies
which bind to the cell surface of keratinocytes. The first
recorded instance of Pemphigus disease was by Hippocra-
tes (460–370 BC) who described pemphigoid fever as
"pemphigodes pyertoi." Galen (131–201 AD) named a pus-
tular disease of the mouth as "febris pemphigodes." In 1791,
Wichmann used the term "pemphigus" to indicate a
pathology characterized by flaccid bullae and painful oral
ulcerations. In 1964 Beutner and Jordon reported autoan-
tibodies in the sera of pemphigus patients, reactive with
an "intercellular substance" of skin and mucosa, by using
indirect immunofluorescence [1,2]. Eventually, in 1990
Amagai, Klaus-Kovtun and Stanley identified the "inter-
cellular substance" as desmoglein-3, a 130-kDa desmo-
somal adhesion molecule [3]. Today the pathogenicity of
anti-Dsg3 autoantibodies is a datum of fact since transfer
of patient derived anti-Dsg3 serum IgG antibodies into
mice induces a bullous skin disease resembling PV [4].
Histopathologically, PV is characterized by suprabasal
intraepidermal bullae with acantholysis and inflamma-
tory infiltrate of eosinophils. Immunopathologically, IgG
and C3 deposits are found in intercellular/cell surface
areas in skin lesions. Typically, Nikolsky's sign is present
in this disease: sheetlike removal of skin by gentle pushing
with a finger [5,6]. Although histologically well character-
ized, the course of the pemphigus pathological events and
the specific pathway of the blistering process is not fully
understood. In parallel, the molecular basis and the bio-
chemical events of the pemphigus pathology remain to be
clearly defined.
Therapeutically, PV treatments include corticosteroids,
immunosuppressive drugs (azathioprine, cyclophospha-
mide, cyclosporine, and methotrexate), anti-inflamma-
tory agents (gold, dapsone, tetracycline and
nicotinamide) [5-12], plasmapheresis [13] and, more
recently, intravenous immunoglobulins [14-17] and
cholinergic agonists [18]. The final goal of these treat-
ments is to reduce inflammation and/or production of the
pathogenic autoreactive antibodies. There are several lim-
itations that make current treatment protocols less than
ideal: 1) no single therapy, other than high-dose steroid
administration, has been reported resolutive so far; 2)
prolonged immunosuppression may be associated with
severe side effects, including an enhanced susceptibility to
opportunistic infections; 3) the efficacy of high-dose ster-
oid administration is transient, and relapses are the rule as
soon as the steroid treatment is discontinued. Moreover,
the side-effects of corticosteroid treatment are numerous
and heavy, one example for all being represented by ster-
oid-induced diabetes [19-21].
In such a context, the need for the development of alter-
native, effective and safe treatments for PV is unquestion-
able and mandatory. In our labs, we are testing the
possibility of applying peptide-immunotherapy targeted
to specific low-similarity protein segments, thereby treat-
ing the disease without the risk of collateral cross reac-
tions [22-31]. Accordingly, in the present approach to PV
peptide immunotherapy we have used a linear low-simi-
larity segment of the protein autoantigen associated to PV,
desmoglein-3 (Dsg3) amino acid 59–60 corresponding to
the sequence REWVKFAKPCRE [32,33]. The low-similar-
ity peptide was defined using a proteome-base computer-
assisted algorithm network in order to identify Dsg3 pep-
tide fragments potentially able to interfere with and/or
stop the PV pathological event chain and, at the same
time, eliminate possible collateral effects due to cross
reactions. Following a series of in vitro and animal experi-
ments [32-34], our studies have progressively focused on
the Dsg349–60REWVKFAKPCRE peptide sequence that 1)
is uniquely expressed in Dsg3 and, consequently, cannot
induce/provoke collateral secondary autoimmune cross-
reactions [22-34]; 2) is hosted in a Dsg3 domain involved
in the intramolecular epitope spreading characterizing the
progression of PV from mucous to muco-cutaneous stage
[35]; 3) does not produce pathogenic antibodies [33].
Here we describe a case report illustrating the potential
therapeutic use of the computer-designed Dsg349–
60REWVKFAKPCRE peptide in PV.
Materials and methods
Peptide description
The EC1/EC2 Dsg349–60REWVKFAKPCRE peptide was
synthesized using standard Fmoc (N-(9-fluorenyl)meth-
oxycarbonyl) solid phase peptide synthesis. Peptide
purity (>95%) was controlled by HPLC, and the molecu-
lar mass of purified peptide confirmed by fast atomic
bombardment mass spectrometry.
Treatment design
Dsg349–60REWVKFAKPCRE peptide was administered by
topical route. A cream formulation of pure vaseline con-
taining 0.1% Dsg349–60REWVKFAKPCRE peptide was pre-
pared under sterile conditions. Peptide immunotherapy
was carried out on a late stage PV patient by using the fol-
lowing provisos: 1) no canonical medical treatment was
discontinued and/or modified; 2) peptide immuno-
therapy was administered under form of topical cream; 3)
the topical peptide treatment was temporally limited to
one week; 4) the topical peptide treatment was locally
limited to only one out of the patient's multiple erosive
skin lesions; 5) the patient was hospitalized and clinically
monitored in order to discontinue the treatment at the
least sign of discomfort and, afterwards, remains under
control for nearly two years past the topical treatment; 6)Journal of Translational Medicine 2006, 4:43 http://www.translational-medicine.com/content/4/1/43
Page 3 of 7
(page number not for citation purposes)
preliminarly, the possibility that the anti-Dsg349–
60REWVKFAKPCRE peptide might be pathogenic (and,
consequently, harmful to the patient) had been excluded
[33].
Patient's history and treatment
The 1-wk topical application of the peptide cream was
conducted at the Department of Dermatology, Faculty of
Medicine, University of Bari in agreement to the Helsinki
declaration, with patient's detailed informed consent, and
applying the guidelines regulating biomedical research
involving human subjects.
The patient (56-year-old, 56 kg) presented with 4-year his-
tory of mucocutaneous PV, with multiple relapses, and
numerous hospitalization, during which he had been
under care at the Dermatology Clinic of the Faculty of
Medicine, University of Bari. The diagnosis of pemphigus
had been confirmed at the onset by excisional biopsy and
histology, Tzanck's cytodiagnostic method, direct immun-
ofluorescene (DIF) and indirect immunofluorescene
(IIF). The latter investigations revealed acantholytic phe-
nomena linked to a high titer of circulating IgG AAbs (titer
≥ 1:400).
Starting in 2001, the patient had been treated with sys-
temic corticosteroids (100 mgs/die deltacortene) plus aza-
thioprine (100 mgs/die) and cyclosporine (300 mgs/die).
When corticosteroid dosage was progressively downs-
caled, disease recurrence occurred at doses lower than 30
mgs/die). Because of collateral treatment effects (diabetes
mellitus, arterial hypertension, corneal ulcers), the patient
also underwent several sessions of plasmapheresis which
led to temporary clinical improvement and reduction in
the anti-Dsg3 AAb titer.
On May 2004, the subject was hospitalized because of a
severe relapse. At this time the patient presented vast areas
of disepithelization, especially on the back, axillary and
inguino-scrotal folds plus numerous erosions in the oral
mucosa. Nikolsky's sign was positive. Blood test revealed
hypochromic anemia, mild hypoproteinemia and hypoc-
alcemia as well as type II diabetes mellitus. The patient
had also signs of infection of the urinary tract.
Given the severe clinical picture, the hospitalized patient
was started on aggressive corticosteroid therapy (as
already administered in the past), administered in 1 g
sodium hydrocortisone hemisuccinate/die by i.v. route
for three consecutive days. Corticosteroids were subse-
quently scaled down to 100 mg/die prednisone, and fur-
ther lowered to topical application of clobetasol
propionate cram twice a day. After 10 days, IFI decreased
by 50% (AAb titer 1:200).
At this time, the Dsg349–60REWVKFAKPCRE peptide
cream (0.1% peptide in pure vaseline) treatment was
started. Specifically, two symmetrical areas hosting PV
lesions (disepithelization, erosions and evident inflam-
mation) were devised on the back (see Fig. 1A), and the
peptide cream was applied twice a day to the lesion on the
right, while the symmetrical eroded lesion on the left
received topical application of clobetasol propionate
cream. The Dsg3 peptide-cream treatment was continued
for 7-days, during which the peptide cream was applied
topically on the right back lesion, twice daily. Afterwards
the patient remained hospitalized and under observation
for a further 10 days.
The patient was discharged from hospital with a reduced
corticosteroid prescription (50 mgs deltacortene/die), fur-
ther reduced to 20 mgs/day (see Table 1) after 5 mo.
Today the patient is still under control and, at nearly 2
years from that unique topical treatment, has not under-
gone any relapse, remains at a regimen of 20 mgs delta-
cortene/day and presents a clinical picture that can be
defined as under control (see data in Table 1).
Results
Scientific rationale of the Dsg349–60REWVKFAKPCRE-
based treatment
Peptide immunotherapy has enormous potential to slow
down the progression of malignant, autoimmune, allergic
and infectious diseases [39-50]. But the consideration of
safety of the treatment is paramount: in recognising the
potential effectiveness of this therapy, it cannot be
stressed enough that great care must be taken when
attempting to suppress/modify any autoimmune diseases
using peptide immunotherapy. In fact, peptides are able
to cause dangerous autoimmune responses if they evoke
cross-reactions with other normal housekeeping proteins
and/or are pathogenic by themselves [51,52].
Given these caveats, the Dsg349–60REWVKFAKPCRE pep-
tide appeared safe and promising of effectiveness since we
have already demonstrated that the linear Dsg349–
60REWVKFAKPCRE peptide sequence corresponds to a
motif having a low degree of sequence similarity to host's
proteome. Theoretically, this would nullify the possibility
Table 1: Corticosteroid dosage and anti-dsg3 AAb level. 
Patient's follow-up.
Time Deltacortene (mgs/die) IIF Titer
Prior to May 2004 100 1:400
May 2004* 50 1:200
November 2004 20 1:100
February 2005 20 1:100
March 2006 20 1:100
* Topical peptide treatment given.Journal of Translational Medicine 2006, 4:43 http://www.translational-medicine.com/content/4/1/43
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of cross-reactions between anti-Dsg349–60  REWVKFAK-
PCRE antibodies and other unrelated host's proteins host-
ing the Dsg3 motif under examination. The possibility
that the linear Dsg349–60REWVKFAKPCRE peptide might
be pathogenic is further to be unlikely by the fact that the
Dsg1–87 portion of the Dsg protein appears not to be
involved in the induction of PV. AAbs from patients at the
earlier stage recognize an epitope located at Dsg387–566 but
not an epitope located at the first 87 amino acids. It is
noted, however, that the autoimmune humoral response
of patients in the later stage of disease can be targeted
towards an epitope located in the first 87 amino acids of
Dsg3 [33]. Moreover, a recent work from our labs has
demonstrated that IgG AAbs elicited against the Dsg349–
60REWVKFAKPCRE peptide do not have pathogenic
potential, providing experimental support to contradict
the possibility that the peptide administration might gen-
erate pathogenic anti-Dsg3 antibodies capable of exhacer-
bating pemphigus pathology.
Clinical results following peptide-cream topical 
application
From the very first days of application, the peptide-treated
lesion showed a higher rate of re-epithelization compared
to the clobetasol propionate-treated area. Peptide treat-
ment lasted 7-days. As illustrated in Fig. 1, the area treated
with the peptide cream shows resolution of the dermatitis,
in contrast to the contralateral lesion which still presents
signs of disepithelization, mostly at the periphery. Careful
clinical examination of the treated lesion put into evi-
dence the following results when compared to non-
treated lesions: a) almost immediate disappearance of the
circular extra-lesion inflammation redness; b) reduction
of lesion size; c) increase of the re-epithelization rate c)
reduction of the erosions present in the lesion, both
numerically and as area extension (Fig. 1B). There was no
evidence of any adverse effect. The patient expressed well-
being and highlighted the higher ease he had in moving
and lying on the body part corresponding to the treated
lesion.
Subsequent monitoring post-peptide cream application
revealed a progressive decrease of anti-Dsg3 AAb titer, as
detailed in Table 1. It is noteworthy that about 2 years
after that unique peptide-therapy topical treatment, anti-
Dsg3 titer still is low (1:100). As importantly, no relapse
has been monitored notwithstanding the patient remains
at a low regimen of corticosteroids (20 mgs/die) (Table
1).Discussion
The "peptide vaccine" concept is based on the identifica-
tion and chemical synthesis of B cell and/or T cell epitopes
that are immunodominant and may induce specific
immune functions (neutralization, killing, help). Peptide
mimics, cyclic peptides, branched peptides, peptomers
(cross-linked peptide polymers) and other complex mul-
Clinical results following Dsg3 peptide-cream topical application Figure 1
Clinical results following Dsg3 peptide-cream topical application. A) Patient's lesions before the peptide treatment. Arrows 
indicate the area selected to be treated with clobetasol propionate (on the left) or the peptide cream (on the right). B) After 1 
wk of clobetasol propionate treatment (on the left) or peptide cream application (on the right).Journal of Translational Medicine 2006, 4:43 http://www.translational-medicine.com/content/4/1/43
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timeric structures, as well as peptides conjugated to other
molecules (see lipopeptides), have been developed and in
a few instances even tested in the attempt of identify effec-
tive peptide sequence/formulations in immunotherapeu-
tical approaches to cancer and autoimmune disease [36-
48]. The simplest peptide form in vaccine formulations is
represented by linear polymers of ~8–24 amino acids.
Linear amino acids sequences offer a more reductionist
approach to evaluate effectiveness and results both in vivo
and in vitro biomedical research [22,23]. Most impor-
tantly, preliminarily to scoring for effectiveness, a peptide
vaccine must be proved to be safe and void of side effects
as a first priority. Unfortunately, several peptide vaccine
immunotherapeutical approaches to date have shown a
concomitant sequela of harmful, sometimes lethal,
autoimmune reactions due to cross reactions with not
only the disease-associated-protein but also other unre-
lated housekeeping proteins [49-52] possibly sharing the
same peptide sequence [24].
As regards PV, the HLA selective presentation of DSG3
peptides in PV has been thoroughly analyzed, starting
from the premise that peptide presentation to T cells may
be important in the initiation or progression of autoim-
mune diseases. Based on the DRB1*0402 binding motif,
seven DSG3 candidate peptides were identified by
Wuchepfennig et al. [53]. Accordingly, previously identi-
fied stimulatory Dsg3 peptides were docked into the bind-
ing groove of constructed atomic models of ten PV
associated, non-associated and protective alleles, in order
to analyze the structural aspects of allele-specific binding
[54]. However, to our knowledge, none of the HLA-bind-
ing DSG3 peptides studied so far has produced possible
therapeutical applications. Rather, additional studies in
PV patients and healthy subjects have further confirmed
that T cell recognition of Dsg3 peptides is tightly restricted
by distinct HLA class II alleles, but, also, have demon-
strated that T cell recognition of distinct Dsg3 peptides is
independent of the development of Pemphigus vulgaris
[55].
Our strategy was to use an in silico technology proteomics-
based platform to identify epitopic peptide sequence(s)
from disease-associated-antigens that share no similarity
with the host proteome [22-34]. By identifying low/no
similarity level peptide sequences, our proteomic
approach offers an effective and safe tool to specifically
identify motifs uniquely expressed in the disease-associ-
ated-protein, in an effort to avoid the possibility of
unwanted cross-reactions.
In applying this scientific rationale to the Pemphigus vul-
garis  associated antigen, Dsg3, we have identified the
Dsg349–60REWVKFAKPCRE peptide sequence as a frag-
ment with low similarity to human proteome [32-34].
Based on this property, Dsg349–60REWVKFAKPCRE pep-
tide is postulated to represent a safe and secure base for
immunotherapy of pemphigus. Consequently we: 1) for-
mulated a topical Dsg349–60REWVKFAKPCRE peptide
cream and 2) elaborated a likewise safe and secure appli-
cation protocol consisting of a 1 wk application time over
a limited application area. This report represents an exem-
plar of the cautions and provisos that have to be observed
for peptide immunotherapy. De facto, the Dsg349–
60REWVKFAKPCRE peptide topical application has given
short- and long-term positive results in terms of lesion
healing and the patient's well being, with an absence of
any adverse effect.
In conclusion, topical treatment with Dsg349–
60REWVKFAKPCRE peptide deserves further clinical inves-
tigation in order to open the way towards a careful, cau-
tious and safe long-term PV immunotherapy by topically
applied, or even parenterally administered, Dsg349–
60REWVKFAKPCRE peptide. More in general, this report
promotes the concept that peptides with low level of sim-
ilarity to the host's proteome might safely be used in
immunotherapy of autoimmune diseases.
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